Background The anticoagulant actions of oral direct factor Xa (FXa) inhibitors can be
inferred from their observed plasma concentrations; however, the steady-state …

Background Atrial fibrillation (AF) is a common tachyarrhythmia in Australia, with a
prevalence over 10% in older patients. AF is the leading preventable cause of ischaemic …

This randomized, double‐blind, placebo‐controlled, ascending single intravenous (IV) bolus‐
dose study evaluated safety, tolerability, pharmacokinetics (PK), and pharmacodynamics …

Apixaban is an oral, direct factor Xa inhibitor under development for secondary prevention in
acute coronary syndrome (ACS). Apixaban's effect on D-dimer and prothrombin fragment 1.2 …

Interpatient variability in the safety and efficacy of oral anticoagulation with warfarin presents
several challenges to clinicians, thus underscoring the emergent need for new orally …

The coagulation system contributes greatly to the evolution of myocardial infarction (MI).
Anticoagulation may reduce the occurrence of MI as monotherapy or with concomitant use of …

Aim Apixaban is an oral factor X a inhibitor approved for stroke prevention in atrial fibrillation
and thromboprophylaxis in patients who have undergone elective hip or knee replacement …

A model‐based approach was used to integrate data from a phase II study in order to
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …

Background Apixaban is an oral, selective, direct factor Xa inhibitor approved for
thromboprophylaxis after orthopedic surgery and stroke prevention in patients with atrial …

Background: There is no established method for monitoring the anticoagulant effects of
apixaban and rivaroxaban. Linear correlation between serum levels and anti-Xa activity has …